• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Lancet: Cytotoxic therapy for severe swine flu A/H1N1

tetano

Editor, Senior Moderator
The Lancet, Volume 376, Issue 9758, Page 2116, 18 December 2010
<Previous Article
doi:10.1016/S0140-6736(10)61345-1Cite or Link Using DOI
Cytotoxic therapy for severe swine flu A/H1N1
Original Text
Prof Jan-Inge Henter MD a Corresponding AuthorEmail Address, Kajsa Palmkvist-Kaijser MD a, Bernhard Holzgraefe MD b, Yenan T Bryceson PhD c, Kenneth Palm?r MD b
In November, 2009, a 31-year-old man presented with fever (40?3?C) and severe dyspnoea. Broad-spectrum antibiotics, and antiviral treatment with oseltamivir, were initiated. PCR confirmed infection with a novel swine-origin influenza A (H1N1) virus. Mechanical ventilation was started 3 days after admission, and veno-arterial extracorporeal membrane oxygenation (ECMO) 8 days later, because of refractory respiratory and circulatory failure. He developed multiple pneumatoceles, recurrent pneumothor ...


http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61345-1/fulltext?rss=yes
 
Back
Top Bottom